Cover Image
市場調查報告書

卡波西氏肉瘤:開發中產品分析

Kaposi Sarcoma - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 361614
出版日期 內容資訊 英文 76 Pages
訂單完成後即時交付
價格
Back to Top
卡波西氏肉瘤:開發中產品分析 Kaposi Sarcoma - Pipeline Review, H1 2017
出版日期: 2017年05月30日 內容資訊: 英文 76 Pages
簡介

卡波西肉瘤是一種癌症,會導致異常組織斑塊在皮膚,口腔,鼻子和喉嚨或其他器官的內部增生。症狀包括通常為紅色或紫色且由癌細胞和血細胞造成的斑塊。在胃腸部位的病變可引起腹痛和腹瀉。

本報告提供卡波西氏肉瘤的治療藥開發情形調查分析,提供開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

卡波西氏肉瘤概要

治療藥的開發

  • 開發中產品的概要
  • 各企業的開發平台
  • 大學/研究機關所開發的開發平台
  • 企業開發中的產品
  • 大學/研究機關開發中的產品

治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

卡波西氏肉瘤的治療藥開發企業

  • Aphios Corp
  • Cannabis Science Inc
  • CytRx Corp
  • LATITUDE Pharmaceuticals Inc
  • RedHill Biopharma Ltd
  • Tumorend LLC
  • VasGene Therapeutics Inc

藥物簡介

卡波西氏肉瘤:暫停中的計劃

卡波西氏肉瘤:開發中止的產品

卡波西氏肉瘤:產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9347IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Kaposi Sarcoma - Pipeline Review, H1 2017, provides an overview of the Kaposi Sarcoma (Infectious Disease) pipeline landscape.

Kaposi's sarcoma is a cancer that causes patches of abnormal tissue to grow under the skin, in the lining of the mouth, nose, and throat or in other organs. Symptoms include patches which are usually red or purple and are made of cancer cells and blood cells. Lesions that develop in the stomach and intestines can cause abdominal pain and diarrhea.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Kaposi Sarcoma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Kaposi Sarcoma (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Kaposi Sarcoma (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Kaposi Sarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 1, 3, 1 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Kaposi Sarcoma (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Kaposi Sarcoma (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Kaposi Sarcoma (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Kaposi Sarcoma (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Kaposi Sarcoma (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Kaposi Sarcoma (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Kaposi Sarcoma (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Kaposi Sarcoma (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Kaposi Sarcoma - Overview
    • Kaposi Sarcoma - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Kaposi Sarcoma - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Kaposi Sarcoma - Companies Involved in Therapeutics Development
    • Aphios Corp
    • Cannabis Science Inc
    • CytRx Corp
    • LATITUDE Pharmaceuticals Inc
    • RedHill Biopharma Ltd
    • Tumorend LLC
    • VasGene Therapeutics Inc
  • Kaposi Sarcoma - Drug Profiles
    • ABC-294640 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • aldoxorubicin hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CM-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CSTATI-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Dermos - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • doxorubicin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • interferon alfa-2a - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • interferon alfa-2b - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • paclitaxel - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptide to Inhibit HAUSP for Lymphoma and Kaposi Sarcoma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TLD-208 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vas-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Kaposi Sarcoma - Dormant Projects
  • Kaposi Sarcoma - Discontinued Products
  • Kaposi Sarcoma - Product Development Milestones
    • Featured News & Press Releases
      • Jun 06, 2016: CytRx Presents Updated Aldoxorubicin Clinical Trial Results at the 2016 American Society of Clinical Oncology Annual Meeting
      • May 26, 2016: $1.8 Million Fast-Track NIH SBIR Grant for Manocept Immunotherapeutics Evaluation in Kaposi's Sarcoma Awarded to Navidea
      • May 03, 2016: Navidea and Macrophage Therapeutics to Provide Development Program Update
      • Apr 20, 2016: CytRx to Present Updated Aldoxorubicin Clinical Trial Data at the American Society of Clinical Oncology Annual Meeting in June 2016
      • Sep 03, 2015: Navidea Awarded $1.8M Fast Track NIH SBIR Grant for Evaluation of a Manocept Agent in Kaposi's Sarcoma
      • Jul 02, 2015: Macrophage Therapeutics Reports Data Demonstrating a Manocept Drug Conjugate Induces Apoptosis in CD206 Positive Kaposi's Sarcoma and Tumor Associated Macrophages
      • Jun 29, 2015: CytRx Announces Presentation of Interim Phase 2 Data for Aldoxorubicin for HIV-Related Kaposi's Sarcoma
      • Jan 20, 2015: CytRx Announces FDA's Removal of Partial Clinical Hold for Aldoxorubicin Clinical Trials Permitting Immediate Enrollment of New Patients
      • Jan 08, 2015: CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results as a Treatment for HIV-Related Kaposi's Sarcoma
      • Jan 23, 2014: CytRx Initiates Phase 2 Clinical Trial with Aldoxorubicin for First-Line Treatment of AIDS-Related Kaposi's Sarcoma
      • Apr 26, 2013: Cannabis Science Announces Preclinical Development Program For CS-TATI-I
      • Nov 12, 2012: Beth Israel Deaconess Medical Center, Harvard Medical School Study Confirms Cannabis Science's Approach To Development Of CS-TATI-1 To Inhibit Kaposi Sarcoma
      • Sep 24, 2012: Cannabis Science Initiates Preclinical Investigation Of CS-TATI-1 For European Studies For Squamous/Basal Cell Carcinomas And Kaposi's Sarcoma
      • Aug 13, 2012: CBIS Initiates GMP Development Plan For CS-TATI-1
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Kaposi Sarcoma, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Kaposi Sarcoma - Pipeline by Aphios Corp, H1 2017
  • Kaposi Sarcoma - Pipeline by Cannabis Science Inc, H1 2017
  • Kaposi Sarcoma - Pipeline by CytRx Corp, H1 2017
  • Kaposi Sarcoma - Pipeline by LATITUDE Pharmaceuticals Inc, H1 2017
  • Kaposi Sarcoma - Pipeline by RedHill Biopharma Ltd, H1 2017
  • Kaposi Sarcoma - Pipeline by Tumorend LLC, H1 2017
  • Kaposi Sarcoma - Pipeline by VasGene Therapeutics Inc, H1 2017
  • Kaposi Sarcoma - Dormant Projects, H1 2017
  • Kaposi Sarcoma - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Kaposi Sarcoma - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Kaposi Sarcoma, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top